[ad_1]
The U.S. Drug Administration (FDA) on Saturday issued an emergency use permit for Regeneron Pharmaceuticals’ anti-COVID-19 antibody therapy, an experimental treatment given to U.S. President Donald Trump, which according to the White House leader helped him. heal, Reuters reports.
Also read: A nightmare winter awaits us: Romanian agriculture has collapsed and production is about to collapse
The cocktail of the two antibodies, casirivimab and imdevimab, can be used to treat mild to moderate symptoms of COVID-19 in patients older than 12 years who are at risk of developing severe cases. It cannot be used in patients with COVID-19 who are hospitalized or who need oxygen, according to dpa, reports Agerpres.
The FDA issued the order after a clinical study of 799 non-hospitalized adults with mild to moderate symptoms of COVID-19.
“Licensing these monoclonal antibody therapies could allow patients to avoid hospitalization and ease the burden on our health care system,” said Stephen Hahn, an FDA official.
Regeneron Pharmaceuticals received more than $ 500 million from the US government to develop the treatment, according to the New York Times.
The first 300,000 doses will be provided free of charge by the government, but patients may have to pay the cost of administering the drug to health facilities, the company said in a statement.
[ad_2]
